USAEUROPEViVE
ABOUTSPONSORSHIPFOUNDATION
Logo Hlth
Logo Hlth
12 Oct 2022 | 02:45 PM GMT

Adoption Beyond Reimbursement for Digital Health in Oncology

Anchored by:

Adam Pellegrini
CEO
KAIA HEALTH

Participants:

Adam Pellegrini CEOKaia Health
Adam Pellegrini
CEOKaia Health
Frank Chindamo FounderLaughMD
Frank Chindamo
FounderLaughMD
Gregoire Guillet Chief Business and Value OfficerWeHealth Digital Medicine
Gregoire Guillet
Chief Business and Value OfficerWeHealth Digital Medicine
Joanna Kemp Digital Health Lead - HematologyBristol Myers Squibb
Joanna Kemp
Digital Health Lead - HematologyBristol Myers Squibb
Jyri Yli-Villamo Head of Pharma Global Strategic PartnershipsKaiku Health
Jyri Yli-Villamo
Head of Pharma Global Strategic PartnershipsKaiku Health
Kevin Darcy Director, Link StrategyVeeva
Kevin Darcy
Director, Link StrategyVeeva
Lindsey Hagan Director, Business DevelopmentBiofourmis
Lindsey Hagan
Director, Business DevelopmentBiofourmis
Masayuki ‘Masa’ Asano Head of Partnership and Business DevelopmentMelon Inc.
Masayuki ‘Masa’ Asano
Head of Partnership and Business DevelopmentMelon Inc.
Ricardo C. Berrios Co-Founder & CEOAdhera Health, Inc.
Ricardo C. Berrios
Co-Founder & CEOAdhera Health, Inc.
Tanja Dowe Managing DirectorAngelini Ventures
Tanja Dowe
Managing DirectorAngelini Ventures

About this Meeting

Are you struggling to get patients and healthcare professionals (HCPs) to adopt your digital health product? Keep reading, this meeting is for you!    

Digital health in oncology can mean many things, improved access to care, better tracking and management of symptoms, and improved treatment of comorbidities. However, this becomes worthless without the proper adoption rates. Reimbursement was usually pointed out as the biggest barrier to digital health adoption, but even when there are reimbursement schemes available, like the DiGA framework in Germany, adoption remains low. So, what else is needed? Join this session to discuss the following:      

  • How can digital health companies in oncology improve patient activation? What is the role of HCPs recommendation, family/caregivers, patient associations, D2C marketing, etc?  
  • Striving in patient experience and long-term engagement: activating patients is one piece of the puzzle, as well as product reimbursement. Once patients are onboarded and reimbursement is secured, how can we ensure long-term adoption? How important are usability and personalization?  
  • Best practices to drive HCP awareness and education: this becomes more challenging in oncology, where there is a wide range of professionals involved. How can we do this efficiently? 
  • It is not all about money; what are the non-financial incentives for  HCPs:   having reimbursement schemes is not enough to engage physicians. What other incentives are needed to make a physician prescribe?